The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Senior appointment

30 Nov 2007 07:11

ViaLogy PLC30 November 2007 VIALOGY PLC APPOINTS HEAD OF SALES & MARKETING London, November 30, 2007 -- ViaLogy PLC (AIM: VIY), a leading innovator ofnetwork-centric, real time signal processing platforms for sensor applications,today announced the appointment of Mr. Robert Kern as Vice President, Sales andMarketing for its wholly-owned American subsidiary company, ViaLogy LLC ('ViaLogy'), of Pasadena, California. This senior appointment reflects the transition of the Company's activities fromresearch and development to the commercialisation of its products. Investmentis being made to establish and develop a strong sales and marketing team tosupport the roll-out of ViaLogy's products, initially SPMTM - Sensor PolicyManager, MicroSPMTM and MPEX Electronic EyeTM. Bob Kern joins ViaLogy from the Science Applications International Corporation(SAIC), a global systems integrator and technical services company, where he wasthe Vice President and UK Strategic Account Manager. Previously, he had seniorbusiness development responsibility for SAIC's Defense Intelligence and Securitybusiness and also ran an SAIC business in Europe with several hundred employeesin seven countries. Mr. Kern has also held senior sales and marketing positionswith Silicon Graphics, Sun Microsystems, and Autometric in the intelligence andsecurity business, serving both commercial and government markets. During adistinguished career as a US Air Force Officer, he led efforts to develop fieldintelligence and integrated security systems and architectures for battlespacemanagement. Commenting on his new position, Bob Kern said: "I am very excited by ViaLogy's potential, its technology and value proposition.I look forward to developing our sales channels and partnerships with systemintegrators to incorporate our sensor policy management software and hardwareproducts, which are designed for safety, integrated security, surveillance andbusiness continuity applications." ViaLogy's CEO, Robert W. Dean, welcomed Bob Kern as the company's newest seniorexecutive, saying: "Bob brings to ViaLogy a deep understanding of our customer and market base, andan on-the-ground appreciation of how ViaLogy's unique technologies will play infuture government and commercial integrated security solutions. "Today, in cooperation with a number of global blue-chip companies we aresupporting multiple sensor integration field trials. Bob's internationalexperience will be key in driving our sales growth." For further information please contact: ViaLogyRobert W Dean, President & CEO - US +1 626-296-6337Terry Bond, Chairman - UK & Europe +44 (0)20 2869 7014 Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defense andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Aug 202310:32 amRNSForm 8.3 - Yourgene Health PLC
1st Aug 20239:23 amRNSForm 8.5 (EPT/RI)
31st Jul 202310:59 amRNSForm 8.3 - Yourgene Health PLC
31st Jul 20239:38 amRNSForm 8.5 (EPT/RI)
28th Jul 202310:53 amRNSForm 8.5 (EPT/RI)
27th Jul 20237:00 amRNSPublication of Scheme Document & current trading
26th Jul 20234:45 pmRNSForm 8.3 - Yourgene Health plc
26th Jul 202310:12 amRNSForm 8.5 (EPT/RI)
26th Jul 20238:45 amRNSForm 8.3 - YOURGENE HEALTH PLC
26th Jul 20237:00 amRNSFive-year contract extension with Illumina
25th Jul 20232:06 pmRNSForm 8.3 - Yourgene Health plc
25th Jul 20239:48 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
25th Jul 20237:00 amRNSForm 8.3 - Yourgene Health Plc
24th Jul 20238:32 amRNSForm 8.3 - Yourgene Health PLC
21st Jul 20238:59 amRNSForm 8.5 (EPT/RI)
20th Jul 202311:44 amRNSForm 8.5 (EPT/RI)
19th Jul 20232:06 pmRNSForm 8.3 - Yourgene Health plc
19th Jul 202312:21 pmRNSRule 2.9 Announcement
19th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
19th Jul 20237:00 amRNSIssue of equity, cancellation of warrants & TVR
18th Jul 20235:15 pmRNSForm 8.5 (EPT/RI) Replacement - Yourgene Health PL
18th Jul 20235:13 pmRNSForm 8.3 - YourGene Health plc
18th Jul 20235:00 pmRNSForm 8.5 (EPT/RI) Replacement
18th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
18th Jul 20238:39 amRNSForm 8.3 - Yourgene Health PLC
17th Jul 20235:00 pmRNSForm 8.3 - Yourgene Health Plc
17th Jul 202312:00 pmRNSForm 8.5 (EPT/RI)
17th Jul 202310:27 amRNSForm 8.5 (EPT/RI)
17th Jul 20239:05 amRNSForm 8.3 - Yourgene Health PLC
17th Jul 20238:15 amRNSForm 8.3 - YOURGENE HEALTH PLC
14th Jul 20232:02 pmRNSForm 8.3 - Yourgene Health plc
14th Jul 202312:02 pmRNSForm 8.5 (EPT/RI)
14th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
14th Jul 202310:36 amRNSForm 8.3 - YOURGENE HEALTH PLC
13th Jul 20235:02 pmRNSForm 8.3 - Yourgene Health PLC - Correction
13th Jul 20234:29 pmRNSForm 8 (OPD) (Yourgene Health Plc)
13th Jul 20232:03 pmRNSForm 8.3 - Yourgene Health plc
13th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
13th Jul 202310:43 amRNSForm 8.3 - Yourgene Health Plc
13th Jul 202310:17 amRNSForm 8.5 (EPT/RI)
13th Jul 20239:02 amRNSForm 8.3 - Yourgene Health PLC
13th Jul 20238:53 amRNSForm 8.3 - Yourgene Health PLC
12th Jul 20232:04 pmRNSForm 8.3 - Yourgene Health plc
12th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
12th Jul 202311:39 amRNSForm 8.3 - Yourgene Health PLC
12th Jul 20239:21 amRNSForm 8.5 (EPT/RI)
12th Jul 20238:44 amRNSForm 8.3 - Yourgene Health PLC
12th Jul 20238:18 amRNSForm 8.3 - Yourgene Health PLC
11th Jul 20232:20 pmRNSForm 8.3 - Yourgene Health plc
11th Jul 202312:46 pmRNSForm 8.3 - Yourgene Health PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.